Nadja Bulbuc

1.1k total citations
9 papers, 870 citations indexed

About

Nadja Bulbuc is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nadja Bulbuc has authored 9 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nadja Bulbuc's work include Monoclonal and Polyclonal Antibodies Research (4 papers), CAR-T cell therapy research (3 papers) and Immunotherapy and Immune Responses (3 papers). Nadja Bulbuc is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), CAR-T cell therapy research (3 papers) and Immunotherapy and Immune Responses (3 papers). Nadja Bulbuc collaborates with scholars based in Germany, Israel and United States. Nadja Bulbuc's co-authors include Günter J. Hämmerling, Shulamit Katzav, M. Feldman, S. Segal, Reinhard Wallich, Frank Momburg, Pieter Spee, Jörn C. Albring, Jacques Neefjes and Jens‐Oliver Koopmann and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Immunity.

In The Last Decade

Nadja Bulbuc

8 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nadja Bulbuc Germany 8 606 271 271 97 97 9 870
Claude Boyer France 18 680 1.1× 310 1.1× 211 0.8× 136 1.4× 35 0.4× 32 993
Jacki Goldman United Kingdom 11 586 1.0× 311 1.1× 146 0.5× 107 1.1× 100 1.0× 14 930
Carla J. Aldrich United States 17 1.1k 1.8× 524 1.9× 229 0.8× 84 0.9× 85 0.9× 28 1.5k
Kent S. Boles United States 12 1.3k 2.1× 384 1.4× 453 1.7× 91 0.9× 68 0.7× 13 1.7k
Giulia Pasqual United States 17 940 1.6× 393 1.5× 174 0.6× 144 1.5× 109 1.1× 24 1.6k
Donna Perry-Lalley United States 11 899 1.5× 407 1.5× 435 1.6× 77 0.8× 133 1.4× 15 1.1k
Yoshizumi Takechi United States 8 666 1.1× 376 1.4× 206 0.8× 263 2.7× 57 0.6× 8 881
Wieland Keilholz Germany 13 526 0.9× 635 2.3× 247 0.9× 68 0.7× 52 0.5× 20 1.0k
John S. Bridgeman United Kingdom 17 664 1.1× 341 1.3× 701 2.6× 98 1.0× 175 1.8× 36 1.2k
Gundo Diedrich United States 15 525 0.9× 530 2.0× 305 1.1× 102 1.1× 67 0.7× 28 1.1k

Countries citing papers authored by Nadja Bulbuc

Since Specialization
Citations

This map shows the geographic impact of Nadja Bulbuc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadja Bulbuc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadja Bulbuc more than expected).

Fields of papers citing papers by Nadja Bulbuc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadja Bulbuc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadja Bulbuc. The network helps show where Nadja Bulbuc may publish in the future.

Co-authorship network of co-authors of Nadja Bulbuc

This figure shows the co-authorship network connecting the top 25 collaborators of Nadja Bulbuc. A scholar is included among the top collaborators of Nadja Bulbuc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadja Bulbuc. Nadja Bulbuc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Schwartz‐Albiez, Reinhard, et al.. (2024). Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies. Cancers. 16(24). 4251–4251.
2.
Moldenhauer, Gerhard, Nadja Bulbuc, Claudia Luckner‐Minden, et al.. (2021). Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Frontiers in Immunology. 12. 719116–719116. 29 indexed citations
3.
Sektioglu, Ibrahim M., Rafael Carretero, Nadja Bulbuc, et al.. (2016). Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells. Cancer Research. 77(2). 291–302. 79 indexed citations
4.
Hoffmann, Sabrina, Markus Hecker, Ilia Louban, et al.. (2010). Single cell force spectroscopy of T cells recognizing a myelin-derived peptide on antigen presenting cells. Immunology Letters. 136(1). 13–20. 19 indexed citations
5.
Louban, Ilia, Dominik Djandji, Guido Wabnitz, et al.. (2009). Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy. Proceedings of the National Academy of Sciences. 106(42). 17852–17857. 96 indexed citations
6.
7.
Koopmann, Jens‐Oliver, Jörn C. Albring, Eva N. Huter, et al.. (2000). Export of Antigenic Peptides from the Endoplasmic Reticulum Intersects with Retrograde Protein Translocation through the Sec61p Channel. Immunity. 13(1). 117–127. 133 indexed citations
8.
Armandola, Elena, Frank Momburg, Marga Nijenhuis, et al.. (1996). A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. European Journal of Immunology. 26(8). 1748–1755. 71 indexed citations
9.
Wallich, Reinhard, Nadja Bulbuc, Günter J. Hämmerling, et al.. (1985). Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection. Nature. 315(6017). 301–305. 347 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026